Plas-Free is a company specializing in blood purification with a focus on critical care. They offer innovative solutions aimed at improving quality of life and enhancing health economy. Their product pipeline includes the ClearPlasma device, which is designed to reduce bleeding by removing plasminogen and tPA from blood products to prevent fibrinolysis during massive bleeding. Another product, the AAPC-300, is targeted at removing ammonia from the bloodstream to treat hepatic encephalopathy and prevent neurological injury by reducing ammonia levels quickly. The company's technology has received funding from the European Union’s Horizon 2020 research and innovation programme. Plas-Free's website includes sections on their management team, board of directors, scientific advisory board, partnerships, intellectual property, and information for physicians. They invite partnerships and provide contact details for further engagement.